Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Hepatic macrophage activation predicts clinical decompensation in chronic liver disease.

Rode A, Nicoll A, Møller HJ, Lim L, Angus PW, Kronborg I, Arachchi N, Gorelik A, Liew D, Kazankov K, Vilstrup H, Grønbæk H.

Gut. 2013 Aug;62(8):1231-2. doi: 10.1136/gutjnl-2012-304135. Epub 2013 Feb 26. No abstract available.

PMID:
23442440
2.

Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis.

Grønbaek H, Sandahl TD, Mortensen C, Vilstrup H, Møller HJ, Møller S.

Aliment Pharmacol Ther. 2012 Jul;36(2):173-80. doi: 10.1111/j.1365-2036.2012.05134.x. Epub 2012 May 16.

3.

Soluble CD163: An age-dependent, anti-inflammatory biomarker predicting outcome in sepsis.

Weiss M, Schneider EM.

Crit Care Med. 2006 Oct;34(10):2682-3. No abstract available.

PMID:
16983269
4.

Serum soluble CD163 predicts risk of type 2 diabetes in the general population.

Møller HJ, Frikke-Schmidt R, Moestrup SK, Nordestgaard BG, Tybjærg-Hansen A.

Clin Chem. 2011 Feb;57(2):291-7. doi: 10.1373/clinchem.2010.154724. Epub 2010 Nov 24.

5.

Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS.

Holland-Fischer P, Grønbæk H, Sandahl TD, Moestrup SK, Riggio O, Ridola L, Aagaard NK, Møller HJ, Vilstrup H.

Gut. 2011 Oct;60(10):1389-93. doi: 10.1136/gut.2010.234542. Epub 2011 May 14.

PMID:
21572121
6.

Soluble CD163.

Møller HJ.

Scand J Clin Lab Invest. 2012 Feb;72(1):1-13. doi: 10.3109/00365513.2011.626868. Epub 2011 Nov 7. Review.

PMID:
22060747
7.

Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin.

Coca A, Bundy KW, Marston B, Huggins J, Looney RJ.

Clin Immunol. 2009 Jul;132(1):10-8. doi: 10.1016/j.clim.2009.02.005. Epub 2009 Mar 17. Review.

PMID:
19297252
8.

Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163.

Møller HJ, Moestrup SK, Weis N, Wejse C, Nielsen H, Pedersen SS, Attermann J, Nexø E, Kronborg G.

Crit Care Med. 2006 Oct;34(10):2561-6.

PMID:
16915112
9.

Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome.

Schaer DJ, Schleiffenbaum B, Kurrer M, Imhof A, Bächli E, Fehr J, Moller HJ, Moestrup SK, Schaffner A.

Eur J Haematol. 2005 Jan;74(1):6-10.

PMID:
15613100
10.

Immunohistochemical phenotyping of liver macrophages in normal and diseased human liver.

Tomita M, Yamamoto K, Kobashi H, Ohmoto M, Tsuji T.

Hepatology. 1994 Aug;20(2):317-25.

PMID:
7519162
11.

Kupffer cell activation and portal hypertension.

Steib CJ.

Gut. 2011 Oct;60(10):1307-8. doi: 10.1136/gut.2011.242560. Epub 2011 Jun 27. No abstract available.

PMID:
21708827
12.

Serum markers of macrophage activation in pre-eclampsia: no predictive value of soluble CD163 and neopterin.

Kronborg CS, Knudsen UB, Moestrup SK, Allen J, Vittinghus E, Møller HJ.

Acta Obstet Gynecol Scand. 2007;86(9):1041-6.

PMID:
17712642
13.

Soluble monocyte cluster domain 163, a new global marker of anti-inflammatory response, is elevated in the first trimester of pregnancy.

Paidas MJ, Ku DH, Davis B, Lockwood CJ, Arkel YS.

J Thromb Haemost. 2004 Jun;2(6):1009-10. No abstract available.

14.

Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease.

Møller HJ, de Fost M, Aerts H, Hollak C, Moestrup SK.

Eur J Haematol. 2004 Feb;72(2):135-9.

PMID:
14962251
15.

The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis.

Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, Brunner HI, Griffin T, Graham TB, Sherry DD, Passo MH, Ramanan AV, Filipovich A, Grom AA.

Arthritis Rheum. 2007 Mar;56(3):965-71.

16.

Kupffer-cell depletion in chronic liver disease: implications for hepatic carcinogenesis.

Manifold IH, Triger DR, Underwood JC.

Lancet. 1983 Aug 20;2(8347):431-3.

PMID:
6135915
17.
18.

Soluble CD163: a marker molecule for monocyte/macrophage activity in disease.

Møller HJ, Aerts H, Grønbaek H, Peterslund NA, Hyltoft Petersen P, Hornung N, Rejnmark L, Jabbarpour E, Moestrup SK.

Scand J Clin Lab Invest Suppl. 2002;237:29-33.

PMID:
12570164
19.

Diagnostic value of serum concentrations of high-mobility group-box protein 1 and soluble hemoglobin scavenger receptor in brucellosis.

Ayarcı AO, Yılmaz E, Sığırlı D, Budak F, Göral G, Oral HB.

Microbiol Immunol. 2013 Feb;57(2):150-8. doi: 10.1111/1348-0421.12016.

20.

Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio.

Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, Martin-Ventura JL, Egido J, Gaussem P, Emmerich J, Michel JB, Blanco-Colio LM, Meilhac O.

Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1253-62. doi: 10.1161/ATVBAHA.110.203364. Epub 2010 Mar 18.

Supplemental Content

Support Center